Paul Averback, MD, DABP, President and CEO
Dr. Paul Averback is the founder, CEO and President of Nymox. Dr. Averback has extensive firsthand knowledge of health care, including as an emergency room physician, family physician, clinic administrator and university Medical Faculty member. In addition to many issued and pending patents, Dr. Averback has published prolifically in the scientific and medical literature on subjects such as Alzheimer's disease, pharmaceuticals, neuropathology, neuroanatomy, diagnostics, vascular disease, oncology, cytology, congenital disease, embryology, geometrical probability and morphometry. Dr. Averback holds a Diploma of the American Board of Pathology with Special Competence in Neuropathology, was a Medical Research Council Postdoctoral Fellow at Cambridge University, England, and was on the Faculty of Medicine at McGill University.
Erik Danielsen, Chief Financial Officer
Erik Danielsen holds an MBA in Finance and Swiss Business Law from the University of Fribourg in Switzerland. He was formerly Senior Auditor for Price Waterhouse in Zurich and subsequently was Equity Strategist for Credit Suisse. He has been acting as an independent health care analyst and consultant, advising both young growth companies as well as private and industrial investors on a variety of subjects including company evaluations, equity financing and operational communication strategies over the past 20 years.